Provider review
VyrarX review
The dual agonist costs 84% more than the semaglutide program.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
From $179/mo semaglutide and $329/mo tirzepatide
Visit VyrarXThe widest proportional step between molecules of any provider here, and switching is a common path.
Price as published
VyrarX
From $179/mo semaglutide and $329/mo tirzepatide
- Vs median
- $4/mo above the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two programs, cleanly described, with what the fee covers stated for each: weekly injections, physician oversight and lifestyle coaching on both. The thing worth noticing is the gap between them. Eighty-four per cent more for the dual agonist is at the wide end of what this category charges, and it matters because switching molecules is a common path rather than an unusual one. People start on semaglutide, plateau or tolerate it poorly, and move across. Anyone who does that here is looking at a hundred and fifty dollars a month more than they started with, which is a decision better made before signing up than discovered afterwards. Both figures are floors introduced by from, so neither is the price at a working dose, and nothing above either is published anywhere. No milligram appears against either program.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You are confident you will stay on semaglutide
- You want physician oversight and lifestyle coaching included in the fee
- You want the two programs described distinctly rather than as one toggle
Look elsewhere if
- You expect to switch molecules — no provider here has a wider step between them
- You want a rate rather than a floor
- You want a dose behind the number
What it actually costs
Price as published
From $179/mo semaglutide and $329/mo tirzepatide
- Vs median
- $4/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. The step between the molecules is proportionally the widest here — 84% more for the dual agonist, against a norm of a third more to a doubling. Switching molecules is a common path rather than a rare one, so if you start on semaglutide, price the second molecule before starting rather than after. No low-dose product, both figures floors, no dose published.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Included
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- States what the fee covers for both programs: injections, oversight and coaching.
- Both molecules are priced openly without an intake.
- The two programs are described distinctly rather than as one product with a toggle.
Pharmacy, labs and oversight
VyrarX does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What VyrarX publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two programs, cleanly described, with what the fee covers stated for each: weekly injections, physician oversight and lifestyle coaching on both. The thing worth noticing is the gap between them. Eighty-four per cent more for the dual agonist is at the wide end of what this category charges, and it matters because switching molecules is a common path rather than an unusual one — people start on semaglutide, plateau or tolerate it poorly, and move. A reader who does that here is looking at a hundred and fifty dollars a month more, which is a decision worth making before starting rather than discovering afterwards. Both figures are floors introduced by from, so neither is the price at a working dose, and nothing above either is published. No milligram appears against either program.
The honest cons
The dual agonist costs 84% more, at the wide end of the category.
- Both figures are floors with no rung above either published.
- No milligram appears against either program.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
VyrarX is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way VyrarX does. Both are partners: we may earn a commission if you start care through these links.
Partner
Direct Meds
From $249/mo sublingual · $297/mo injection
Standard plan, self-directed low dose
FDA warning letter · Direct Meds · September 2025 · addressed to directmeds.com, Inc. dba DirectMeds. Details in our review.
Partner
Peter MD
$149/mo GLP1+B12 · $249/mo tirz (quarterly)
Standard plan, self-directed low dose
Where this sits
#344 of 548
Ordered with the companies that pay us first, and VyrarX is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Strut Health
$99/mo sema lozenge (auto-refill)
FDA warning letter · Strut Health · February 2026 · addressed to Strut Health, LLC dba Strut. Details in our review.
- Vs median
- $76/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Strut Health review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.